Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R)
Elite Pharmaceuticals (OTCQB: ELTP) has launched its generic version of Vyvanse® (Lisdexamfetamine Disylate) for treating attention deficit hyperactivity disorder (ADHD). The product is available in seven different strengths: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg capsules. The generic drug will be marketed and sold under the Elite Laboratories label. According to IQVIA data, the original drug recorded annual sales of approximately $4.3 billion for the twelve months ending October 2024.
Elite Pharmaceuticals (OTCQB: ELTP) ha lanciato la sua versione generica di Vyvanse® (Lisdexamfetamina Disilato) per il trattamento del disturbo da deficit di attenzione e iperattività (ADHD). Il prodotto è disponibile in sette diverse concentrazioni: capsule da 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg e 70 mg. Il farmaco generico sarà commercializzato e venduto sotto l'etichetta Elite Laboratories. Secondo i dati di IQVIA, il farmaco originale ha registrato vendite annuali di circa $4,3 miliardi per i dodici mesi conclusi a ottobre 2024.
Elite Pharmaceuticals (OTCQB: ELTP) ha lanzado su versión genérica de Vyvanse® (Lisdesanfetamina Disilato) para el tratamiento del trastorno por déficit de atención e hiperactividad (TDAH). El producto está disponible en siete diferentes concentraciones: cápsulas de 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg y 70 mg. El medicamento genérico se comercializará y venderá bajo la etiqueta de Elite Laboratories. Según los datos de IQVIA, el medicamento original registró ventas anuales de aproximadamente $4.3 mil millones durante los doce meses que terminaron en octubre de 2024.
엘리트 제약(OTCQB: ELTP)이 주의력 결핍 과다 행동장애(ADHD) 치료를 위한 Vyvanse® (리스데사메페타민 디실레이트)의 제네릭 버전을 출시했습니다. 이 제품은 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg의 일곱 가지 다양한 용량으로 제공됩니다. 제네릭 약물은 엘리트 연구소 브랜드로 마케팅되고 판매될 예정입니다. IQVIA 데이터에 따르면, 원래 약물은 2024년 10월에 종료된 12개월 동안 약 $43억의 연간 판매를 기록했습니다.
Elite Pharmaceuticals (OTCQB: ELTP) a lancé sa version générique de Vyvanse® (Lisdexamfétamine Disilate) pour le traitement du trouble du déficit de l'attention avec hyperactivité (TDAH). Le produit est disponible en sept dosages différents : gélules de 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg et 70 mg. Le médicament générique sera commercialisé et vendu sous l'étiquette des Laboratoires Elite. Selon les données d'IQVIA, le médicament original a enregistré des ventes annuelles d'environ 4,3 milliards de dollars pour les douze mois se terminant en octobre 2024.
Elite Pharmaceuticals (OTCQB: ELTP) hat seine generische Version von Vyvanse® (Lisdexamfetamin-Diisilat) zur Behandlung von Aufmerksamkeitsdefizit-Hyperaktivitätsstörung (ADHS) auf den Markt gebracht. Das Produkt ist in sieben verschiedenen Stärken erhältlich: Kapseln zu 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg und 70 mg. Das Generikum wird unter dem Label Elite Laboratories vermarktet und verkauft. Laut IQVIA-Daten betrugen die jährlichen Verkaufszahlen des Originalmedikaments etwa 4,3 Milliarden US-Dollar für die zwölf Monate bis Oktober 2024.
- Launch of generic version of Vyvanse, a drug with $4.3B annual market size
- Complete product line with seven different dosage strengths
- Entry into the lucrative ADHD treatment market
- Will face competition from other generic manufacturers in a crowded market
Northvale, New Jersey--(Newsfile Corp. - December 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Vyvanse® (Lisdexamfetamine Disylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules. The product is indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This product is marketed and sold under the Elite Laboratories, Inc. label.
IQVIA reported annual sales for the twelve months ending October 2024 of approximately
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite's product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties, and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations
518-398-6222
Dianne@elitepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235227
FAQ
What is the market size for Vyvanse that ELTP's generic version is targeting?
What strengths is ELTP offering for their generic Vyvanse?
When did ELTP launch its generic version of Vyvanse?
What medical condition does ELTP's generic Vyvanse treat?
